Back to Newsroom
Back to Newsroom

CLASS ACTION UPDATE for VRCA, UL and WEBR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Wednesday, 03 August 2022 12:30 PM

Levi & Korsinsky, LLP

Topic:
Lawsuits

NEW YORK, NY / ACCESSWIRE / August 3, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

VRCA Shareholders Click Here: https://www.zlk.com/pslra-1/verrica-pharmaceuticals-inc-loss-submission-form?prid=30535&wire=1
UL Shareholders Click Here: https://www.zlk.com/pslra-1/unilever-plc-loss-submission-form?prid=30535&wire=1
WEBR Shareholders Click Here: https://www.zlk.com/pslra-1/weber-inc-information-request-form?prid=30535&wire=1

* ADDITIONAL INFORMATION BELOW *

Levi & Korsinsky, LLP, Wednesday, August 3, 2022, Press release picture

Verrica Pharmaceuticals, Inc. (NASDAQ:VRCA)
VRCA Lawsuit on behalf of: investors who purchased May 28, 2021 - May 24, 2022
Lead Plaintiff Deadline : August 5, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/verrica-pharmaceuticals-inc-loss-submission-form?prid=30535&wire=1

According to the filed complaint, during the class period, Verrica Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) there were manufacturing deficiencies at the facility where Verrica's contract manufacturer produced a bulk solution for the Company's lead product candidate, VP-102; (2) these deficiencies were not remediated when Verrica resubmitted its New Drug Application for VP-12 for molluscum; (3) the foregoing presented significant risks to Verrica obtaining regulatory approval of VP-102 for molluscum; and (4) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Unilever PLC (NYSE:UL)
This lawsuit is on behalf of all persons who purchased or otherwise acquired Unilever American Depositary Receipts between September 2, 2020 and July 21, 2021, inclusive.
Lead Plaintiff Deadline : August 15, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/unilever-plc-loss-submission-form?prid=30535&wire=1

According to the filed complaint, a) in July 2020, the board of Ben & Jerry's, one of Unilever's marquee brands, passed a resolution to end sales of its ice cream in "Occupied Palestinian Territory" ; and b) this boycott decision risked adverse governmental actions for violations of laws, executive orders, or resolutions aimed at discouraging boycotts, divestment, and sanctions of Israel adopted by 35 U.S. states.

Weber Inc. (NYSE:WEBR)
This lawsuit is on behalf of persons and entities that purchased or otherwise acquired Weber Class A common stock pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's August 2021 initial public offering.
Lead Plaintiff Deadline : September 27, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/weber-inc-information-request-form?prid=30535&wire=1

According to the filed complaint, (1) Weber was reasonably likely to implement price increases; (2) as a result, consumer demand for Weber's products was reasonably likely to decrease; (3) due to the resulting inventory buildup, Weber was reasonably likely to run promotions to "enhance retail sell through"; (4) the foregoing would adversely impact Weber's financial results; and (5) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

Topic:
Lawsuits
Back to newsroom
Back to Newsroom
Share by: